Увійти

Готові списки джерел за темами / Future progression / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Future progression.

Статті в журналах з теми "Future progression"

Автор: Grafiati

Опубліковано: 10 січня 2023

Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Future progression".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Sapolsky, Daisy, Kimiko Domoto-Reilly, Alyson Negreira, Michael Brickhouse, Scott McGinnis, and Bradford C. Dickerson. "Monitoring progression of primary progressive aphasia: current approaches and future directions." Neurodegenerative Disease Management 1, no. 1 (February 2011): 43–55. http://dx.doi.org/10.2217/nmt.11.2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Hassan, Hafiz Ali. "Takaful models: origin, progression and future." Journal of Islamic Marketing 11, no. 6 (November 23, 2019): 1801–19. http://dx.doi.org/10.1108/jima-04-2018-0078.

Повний текст джерела

Анотація:

Purpose The concept of Takaful has a long history. It is linked with the era of Prophet Muhammad 1,400 years ago. The globalization and development of socio-economic systems have made business activities more complex in response to emerging human needs and requirements. Similarly, Takaful insurance has fully commercialized and become an important indicator of the international financial market. The purpose of this study is to understand the Takaful mechanism and progression of its procedures to date since its inception. Design/methodology/approach This study seeks to examine the origin, evolution and historical developments of Takaful mechanism, operations, models and governing framework with extant literature review from previous studies and current practices. Findings The modern Takaful insurance first began in Sudan back in 1979. The Takaful operations must abide by the Sharia laws and work under the supervision of the Sharia Supervisory Board. Since its evolution, Sharia scholars have introduced various Takaful models that are going to be explained in this study. Moreover, several Islamic organizations, including the “Islamic Financial Services Board” and the “Accounting and Auditing Organization for Islamic Financial Institutions,” have provided guidelines and supervision to develop and strengthen the Takaful industry further. The study acknowledges Takaful as a growing insurance industry with huge potential and promising future in both Pakistan and the international market. Practical implications During the analysis, various deficiencies and loopholes were identified, which are responsible for the unmatched growth of conventional insurance. They can be eliminated with the joint efforts of industrial players, Sharia scholars and Takaful insurance companies. Hence, Islamic scholars and academic researchers are encouraged to develop and modify the current practices of Takaful mechanism according to current market demands and consumer approach. The research efforts will help Takaful operators to develop more innovative Takaful products adhering Sharia compliance. Consequently, it will help to access more consumer market and further enhances the Takaful growth. Originality/value This study is an effort to provide a basic understanding of the mechanism of Takaful models. The study helps to comprehend how Takaful models have evolved and been modified over the course of time. Moreover, it provides a base for further development and improvement in current practices of Takaful models, which will result in increased progress for the Takaful industry.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Ohno, Takayuki, Youji Nagai, and Masanori Fukushima. "Progression and future of translational research in Japan." Folia Pharmacologica Japonica 135, no. 5 (2010): 190–93. http://dx.doi.org/10.1254/fpj.135.190.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Lavinsky, Fabio, Gadi Wollstein, Jenna Tauber, and Joel S. Schuman. "The Future of Imaging in Detecting Glaucoma Progression." Ophthalmology 124, no. 12 (December 2017): S76—S82. http://dx.doi.org/10.1016/j.ophtha.2017.10.011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Healy, Brian C., Bonnie I. Glanz, Elyse Swallow, James Signorovitch, Kaitlin Hagan, Diego Silva, Corey Pelletier, Tanuja Chitnis, and Howard Weiner. "Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis." Multiple Sclerosis Journal - Experimental, Translational and Clinical 7, no. 2 (April 2021): 205521732199907. http://dx.doi.org/10.1177/2055217321999070.

Повний текст джерела

Анотація:

Background Although confirmed disability progression (CDP) is a common outcome in multiple sclerosis (MS) clinical trials, its predictive value for long-term outcomes is uncertain. Objective To investigate whether CDP at month 24 predicts subsequent disability accumulation in MS. Methods The Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women’s Hospital includes participants with relapsing-remitting MS or clinically isolated syndrome with Expanded Disability Status Scale (EDSS) scores ≤5 (N = 1214). CDP was assessed as a predictor of time to EDSS score 6 (EDSS 6) and to secondary progressive MS (SPMS) using a Cox proportional hazards model; adjusted models included additional clinical/participant characteristics. Models were compared using Akaike’s An Information Criterion. Results CDP was directionally associated with faster time to EDSS 6 in univariate analysis (HR = 1.61 [95% CI: 0.83, 3.13]). After adjusting for month 24 EDSS, CDP was directionally associated with slower time to EDSS 6 (adjusted HR = 0.65 [0.32, 1.28]). Models including CDP had worse fit statistics than those using EDSS scores without CDP. When models included clinical and magnetic resonance imaging measures, T2 lesion volume improved fit statistics. Results were similar for time to SPMS. Conclusions CDP was less predictive of time to subsequent events than other MS clinical features.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Yang, Liquan, and Lei Xu. "GPR56 in cancer progression: current status and future perspective." Future Oncology 8, no. 4 (April 2012): 431–40. http://dx.doi.org/10.2217/fon.12.27.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Torem, Moshe S. "“Back from the Future”: A Powerful Age-Progression Technique." American Journal of Clinical Hypnosis 35, no. 2 (October 1992): 81–88. http://dx.doi.org/10.1080/00029157.1992.10402990.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Nierengarten, M. B., and D. van der Heijde. "FUTURE 1: Secukinumab Inhibits Radiographic Disease Progression in PsA." MD Conference Express 14, no. 51 (December 1, 2014): 15–17. http://dx.doi.org/10.1177/155989771451012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Kuchma, I. L. "Uremic toxins. Back to the future." KIDNEYS 10, no. 2 (July 1, 2021): 78–87. http://dx.doi.org/10.22141/2307-1257.10.2.2021.234323.

Повний текст джерела

Анотація:

In the review, the author returns to the topic of uremia and uremic toxins, their importance for practitioners in the treatment using renal replacement therapies, gives a modern look at their classification, place during the onset and development of pathological processes in the progression of chronic kidney disease. However, current guidelines and studies for the treatment of chronic kidney disease indicate a lack of attention to the role and importance of uremic toxins in the predialysis stages of uremia treatment, in particular to the possible damaging effects of substances retained in the body with reduced glomerular filtration, directly to the renal function. The tables with the list of uremic toxins according to their classification are presented. References are made to the results of clinical and laboratory studies of uremic toxins, their impact on the general clinical picture of uremia and ways of their influence on the progression of chronic kidney disease and the further progression of the clinical picture of uremia. Attention is drawn to the fact that substances recognized as uremic toxins are present in healthy individuals without manifestations of their negative effects, and therefore the opinion is expressed about the need to study the physiological significance of these solvents under normal glomerular filtration. The question arises about the consideration of the factors of uremic toxins impact as a point of application in terms of the progression of chronic kidney disease and the use of this knowledge in renoprotective therapy in the predialysis stages of chronic kidney disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Colman, Howard. "Future Directions in Glioblastoma Therapy." American Society of Clinical Oncology Educational Book, no. 32 (June 2012): 108–11. http://dx.doi.org/10.14694/edbook_am.2012.32.49.

Повний текст джерела

Анотація:

Overview: The standard of care for both newly diagnosed and recurrent glioblastoma (GBM) patients has changed significantly in the past 10 years. Surgery followed by radiation and concurrent and adjuvant temozolomide is now the well-established standard treatment for newly diagnosed GBM. More recently, bevacizumab has become a mainstay of treatment for recurrent GBM. However, despite these advances and significant improvements in patient outcomes, the management and treatment of GBM patients remains a challenging and frustrating endeavor. Difficulties in interpretation of imaging changes after initial treatment, as well as the effects of antiangiogenic agents like bevacizumab on MRI characteristics, can make even the determination of disease progression complicated in multiple situations. Although a high percentage of patients benefit from antiangiogenic therapy in terms of radiographic response and progression-free survival, the effects of bevacizumab on prolonging overall survival remain controversial. Furthermore, tumor progression after treatment with antiangiogenic agents carries a particularly poor prognosis and there is a general lack of effective therapies for this group of patients. These limitations in terms of standard treatments contrast with a relative wealth of new information regarding the molecular underpinnings of GBM. Data from several large-scale efforts to molecularly profile GBM tumors including The Cancer Genome Atlas (TCGA) project have helped define specific molecular subtypes of GBM with distinct biology and clinical outcomes. These findings are helping to refine our understanding of the molecular heterogeneity and pathogenesis of these tumors and provide a basis for the future development of rational and targeted therapies for specific tumor subtypes.

Стилі APA, Harvard, Vancouver, ISO та ін.

11

R, Singh. "MicroRNA s as Biomarker of Alzheimer’s Disease: Promises and Future Prospect." Neurology & Neurotherapy Open Access Journal 6, no. 1 (2021): 1–10. http://dx.doi.org/10.23880/nnoaj-16000158.

Повний текст джерела

Анотація:

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder occurring in the elderly population. Millions of people in the age group of 60 and above are affected by Alzheimer’s disease worldwide. Damage caused by disease is currently irreversible and incurable. Early-onset and diagnosis of AD could help in delaying the progression of the disease. Earlier AD was diagnosed by clinical assessment and postmortem brain pathology. Therefore, improved approaches are required to sensitively track disease development and therapeutic efficacy. The pathological presence of ß amyloid plaques and Tau neurofibrillary tangles in cerebrospinal fluid (CSF) is the hallmark of detection. MicroRNAs (miRNAs), a 19-22 nucleotide noncoding RNAs circulating in the blood, regulates gene expression by protein repression. miRNAs are key regulators of gene expression in various biological processes and is emerging as a novel prognostic biomarker in various diseases. Recent evidence suggests the role of miRNAs in disease progression and pathogenesis of AD. Five databases, PubMed” MEDLINE, EMBASE, Web of Sciences, and Cochrane Library, were searched, using a combination of Mesh database or Emtree headings and free-text terms, to identify literature relating to miRNAs in Alzheimer’s disease. The comprehensive online electronic databases, only peer-reviewed, full-text original research articles including English literature, were included in the current review. The studies followed the inclusion criteria were critically assessed and checked using the PRISMA tool. In this review role of miRNAs as potential biomarkers in AD progression and pathogenesis will be covered with its elaborative function as a novel prognostic biomarker and its future prospects in the clinical implication of the same.

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Ritz, Eberhard, Michael Schömig, and Jürgen Wagner. "Counteracting progression of renal disease: A look into the future." Kidney International 57 (April 2000): S71—S76. http://dx.doi.org/10.1046/j.1523-1755.2000.07513.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Konstan, Michael W., Jeffrey S. Wagener, and Donald R. VanDevanter. "Characterizing aggressiveness and predicting future progression of CF lung disease." Journal of Cystic Fibrosis 8 (June 2009): S15—S19. http://dx.doi.org/10.1016/s1569-1993(09)60006-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Ritz, Eberhard, Michael Schomig, and Jurgen Wagner. "Counteracting progression of renal disease: A look into the future." Kidney International 57, s75 (April 2000): 71–76. http://dx.doi.org/10.1046/j.1523-1755.57.s75.13.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Lam, Jules Y. T., Jean-Gilles Latour, Jacques Lespérance, and David Waters. "Platelet aggregation, coronary artery disease progression and future coronary events." American Journal of Cardiology 73, no. 5 (February 1994): 333–38. http://dx.doi.org/10.1016/0002-9149(94)90004-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Kisková, Terézia, Felicitas Mungenast, Mária Suváková, Walter Jäger, and Theresia Thalhammer. "Future Aspects for Cannabinoids in Breast Cancer Therapy." International Journal of Molecular Sciences 20, no. 7 (April 3, 2019): 1673. http://dx.doi.org/10.3390/ijms20071673.

Повний текст джерела

Анотація:

Cannabinoids (CBs) from Cannabis sativa provide relief for tumor-associated symptoms (including nausea, anorexia, and neuropathic pain) in the palliative treatment of cancer patients. Additionally, they may decelerate tumor progression in breast cancer patients. Indeed, the psychoactive delta-9-tetrahydrocannabinol (THC), non-psychoactive cannabidiol (CBD) and other CBs inhibited disease progression in breast cancer models. The effects of CBs on signaling pathways in cancer cells are conferred via G-protein coupled CB-receptors (CB-Rs), CB1-R and CB2-R, but also via other receptors, and in a receptor-independent way. THC is a partial agonist for CB1-R and CB2-R; CBD is an inverse agonist for both. In breast cancer, CB1-R expression is moderate, but CB2-R expression is high, which is related to tumor aggressiveness. CBs block cell cycle progression and cell growth and induce cancer cell apoptosis by inhibiting constitutive active pro-oncogenic signaling pathways, such as the extracellular-signal-regulated kinase pathway. They reduce angiogenesis and tumor metastasis in animal breast cancer models. CBs are not only active against estrogen receptor-positive, but also against estrogen-resistant breast cancer cells. In human epidermal growth factor receptor 2-positive and triple-negative breast cancer cells, blocking protein kinase B- and cyclooxygenase-2 signaling via CB2-R prevents tumor progression and metastasis. Furthermore, selective estrogen receptor modulators (SERMs), including tamoxifen, bind to CB-Rs; this process may contribute to the growth inhibitory effect of SERMs in cancer cells lacking the estrogen receptor. In summary, CBs are already administered to breast cancer patients at advanced stages of the disease, but they might also be effective at earlier stages to decelerate tumor progression.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Sippey, Megan, Wanda Lam, Ahmed Ali, and Jeffrey Marks. "Surgical Endoscopy: Future Directions." Digestive Disease Interventions 02, no. 04 (November 28, 2018): 383–87. http://dx.doi.org/10.1055/s-0038-1675753.

Повний текст джерела

Анотація:

AbstractSince the introduction of the modern endoscope in 1957, numerous advances have been made in its use. The endoscope has transitioned from a primarily diagnostic tool at its inception, to now offering a plethora of therapeutic interventions including Natural Orifice Transluminal Endoscopic Surgery (NOTES). Advances in the endoscope, endoscopic imaging modalities, and therapeutic tools and platforms have contributed to recent, and upcoming, progression in NOTES. Current states of these advancements are reviewed.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Carriazo, Sol, Maria Vanessa Perez-Gomez, Adrian Cordido, Miguel Angel García-González, Ana Belen Sanz, Alberto Ortiz, and Maria Dolores Sanchez-Niño. "Dietary Care for ADPKD Patients: Current Status and Future Directions." Nutrients 11, no. 7 (July 12, 2019): 1576. http://dx.doi.org/10.3390/nu11071576.

Повний текст джерела

Анотація:

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic nephropathy, and tolvaptan is the only therapy available. However, tolvaptan slows but does not stop disease progression, is marred by polyuria, and most patients worldwide lack access. This and recent preclinical research findings on the glucose-dependency of cyst-lining cells have renewed interest in the dietary management of ADPKD. We now review the current dietary recommendations for ADPKD patients according to clinical guidelines, the evidence base for those, and the potential impact of preclinical studies addressing the impact of diet on ADPKD progression. The clinical efficacy of tolvaptan has put the focus on water intake and solute ingestion as modifiable factors that may impact tolvaptan tolerance and ADPKD progression. By contrast, dietary modifications suggested to ADPKD patients, such as avoiding caffeine, are not well supported and their impact is unknown. Recent studies have identified a chronic shift in energy production from mitochondrial oxidative phosphorylation to aerobic glycolysis (Warburg effect) as a contributor to cyst growth, rendering cyst cells exquisitely sensitive to glucose availability. Therefore, low calorie or ketogenic diets have delayed preclinical ADPKD progression. Additional preclinical data warn of potential negative impact of excess dietary phosphate or oxalate in ADPKD progression.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

C, Meintjes, Niemann Struweg I, and F. de Wet G. "South African corporate communication practice and its obstacles for future progression." African Journal of Business Management 6, no. 51 (December 26, 2012): 12043–51. http://dx.doi.org/10.5897/ajbm12.333.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Yang, Yongzhi, Peng Junjie, Cai Sanjun, and Yanlei Ma. "Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions." Journal of Cancer 8, no. 16 (2017): 3212–25. http://dx.doi.org/10.7150/jca.19794.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Pae, Chi-Un. "Taking a Responsibility for Future Progression of Clinical Psychopharmacology and Neuroscience." Clinical Psychopharmacology and Neuroscience 18, no. 2 (May 31, 2020): 172–73. http://dx.doi.org/10.9758/cpn.2020.18.2.172.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Sidharta, Samuel L., Timothy J. Baillie, Stuart Howell, Stephen J. Nicholls, Natalie Montarello, Satoshi Honda, Daisuke Shishikura, et al. "Evaluation of human coronary vasodilator function predicts future coronary atheroma progression." Heart 104, no. 17 (March 1, 2018): 1439–46. http://dx.doi.org/10.1136/heartjnl-2017-312579.

Повний текст джерела

Анотація:

ObjectiveCoronary vasodilator function and atherosclerotic plaque progression have both been shown to be associated with adverse cardiovascular events. However, the relationship between these factors and the lipid burden of coronary plaque remains unknown. These experiments focus on investigating the relationship between impaired coronary vasodilator function (endothelium dependent (salbutamol) and endothelium independent (glyceryl trinitrate)) and the natural history of atheroma plaque progression and lipid burden using dual modality intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) imaging.Methods33 patients with stable chest pain or acute coronary syndrome underwent serial assessment of coronary vasodilator function and intracoronary plaque IVUS and NIRS imaging. Coronary segmental macrovascular response (% change segmental lumen volume (ΔSLV)), plaque burden (per cent atheroma volume (PAV)), lipid core (lipid-rich plaque (LRP) and lipid core burden index (LCBI)) were measured at baseline and after an interval of 12–18 months (n=520 segments).ResultsLipid-negative coronary segments which develop into LRP over the study time period demonstrated impaired endothelial-dependent function (−0.24±2.96 vs 5.60±1.47%, P=0.04) and endothelial-independent function (13.91±4.45 vs 21.19±3.19%, P=0.036), at baseline. By multivariate analysis, endothelial-dependent function predicted ∆LCBI (β coefficient: −3.03, 95% CI (−5.81 to −0.25), P=0.033) whereas endothelial-independent function predicted ∆PAV (β coefficient: 0.07, 95% CI (0.04 to 0.10), P<0.0001).ConclusionsEpicardial coronary vasodilator function is a determinant of future atheroma progression and composition irrespective of the nature of clinical presentation.Trial registration numberACTRN12612000594820, Post-results.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Lee, Chi‐Ho, and Karen Siu Ling Lam. "Biomarkers of progression in diabetic nephropathy: The past, present and future." Journal of Diabetes Investigation 6, no. 3 (February 13, 2015): 247–49. http://dx.doi.org/10.1111/jdi.12329.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

McCutcheon, Stephanie. "Leading Change: Progression to the Future at Hospital Sisters Health System." Frontiers of Health Services Management 26, no. 2 (2009): 9–19. http://dx.doi.org/10.1097/01974520-200910000-00003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Islam, Md Shafiqul, Marwa K. Qaraqe, Samir Brahim Belhaouari, and Muhammad A. Abdul-Ghani. "Advanced Techniques for Predicting the Future Progression of Type 2 Diabetes." IEEE Access 8 (2020): 120537–47. http://dx.doi.org/10.1109/access.2020.3005540.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Prasad, Ganapathy A., Ajay Bansal, Prateek Sharma та Kenneth K. Wang. "Predictors of Progression in Barrettʼs Esophagus: Current Knowledge and Future Directions". American Journal of Gastroenterology 105, № 7 (липень 2010): 1490–502. http://dx.doi.org/10.1038/ajg.2010.2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Mackey, David A. "Myopia—The future progression of myopia: Seeing where we are going." Ophthalmic Genetics 37, no. 4 (October 1, 2016): 361–65. http://dx.doi.org/10.1080/13816810.2016.1232416.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Salte, K., V. Todorovic, J. Wetter, V. E. Scott, K. Smith, M. Lowe, M. Rosenblum, J. Gudjonsson, P. Honore, and R. W. Dunstan. "868 Histologic progression of hidradenitis suppurativa: Implications for future therapeutic intervention." Journal of Investigative Dermatology 139, no. 5 (May 2019): S150. http://dx.doi.org/10.1016/j.jid.2019.03.944.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Tanaka, Shinya. "Current and Future Perspectives in Cardiac Rehabilitation." Journal of Personalized Medicine 12, no. 9 (September 15, 2022): 1510. http://dx.doi.org/10.3390/jpm12091510.

Повний текст джерела

Анотація:

To reduce the morbidity and mortality of cardiac diseases, patients undergo cardiac rehabilitation consisting of a series of interventions to optimize their physical, psychological, and social functioning and to stabilize, slow, or reverse the progression of atherosclerosis underlying their condition [...]

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Wickens, Zoe. "In Focus: The future of artificial intelligence in optics." Optician 2018, no. 8 (August 2018): 182341–1. http://dx.doi.org/10.12968/opti.2018.8.182341.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Ajarrag, Samy, and Yves St-Pierre. "Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment." Cancers 13, no. 21 (November 4, 2021): 5533. http://dx.doi.org/10.3390/cancers13215533.

Повний текст джерела

Анотація:

Traditional wisdom suggests that galectins play pivotal roles at different steps in cancer progression. Galectins are particularly well known for their ability to increase the invasiveness of cancer cells and their resistance to drug-induced cell death. They also contribute to the development of local and systemic immunosuppression, allowing cancer cells to escape the host’s immunological defense. This is particularly true in glioma, the most common primary intracranial tumor. Abnormally high production of extracellular galectins in glioma contributes to the establishment of a strong immunosuppressive environment that favors immune escape and tumor progression. Considering the recent development and success of immunotherapy in halting cancer progression, it is logical to foresee that galectin-specific drugs may help to improve the success rate of immunotherapy for glioma. This provides a new perspective to target galectins, whose intracellular roles in cancer progression have already been investigated thoroughly. In this review, we discuss the mechanisms of action of galectins at different steps of glioma progression and the potential of galectin-specific drugs for the treatment of glioma.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Godefa, Tesfay M., Sarah Derks, and Victor L. J. L. Thijssen. "Galectins in Esophageal Cancer: Current Knowledge and Future Perspectives." Cancers 14, no. 23 (November 24, 2022): 5790. http://dx.doi.org/10.3390/cancers14235790.

Повний текст джерела

Анотація:

Esophageal cancer is a disease with poor overall survival. Despite advancements in therapeutic options, the treatment outcome of esophageal cancer patients remains dismal with an overall 5-year survival rate of approximately 20 percent. To improve treatment efficacy and patient survival, efforts are being made to identify the factors that underlie disease progression and that contribute to poor therapeutic responses. It has become clear that some of these factors reside in the tumor micro-environment. In particular, the tumor vasculature and the tumor immune micro-environment have been implicated in esophageal cancer progression and treatment response. Interestingly, galectins represent a family of glycan-binding proteins that has been linked to both tumor angiogenesis and tumor immunosuppression. Indeed, in several cancer types, galectins have been identified as diagnostic and/or prognostic markers. However, the role of galectins in esophageal cancer is still poorly understood. Here, we summarize the current literature with regard to the expression and potential functions of galectins in esophageal cancer. In addition, we highlight the gaps in the current knowledge and we propose directions for future research in order to reveal whether galectins contribute to esophageal cancer progression and provide opportunities to improve the treatment and survival of esophageal cancer patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Grigoraș, Adriana, Raluca Anca Balan, Irina-Draga Căruntu, Simona Eliza Giușcă, Ludmila Lozneanu, Roxana Elena Avadanei, Andreea Rusu, Laura Adriana Riscanu, and Cornelia Amalinei. "Perirenal Adipose Tissue—Current Knowledge and Future Opportunities." Journal of Clinical Medicine 10, no. 6 (March 21, 2021): 1291. http://dx.doi.org/10.3390/jcm10061291.

Повний текст джерела

Анотація:

The perirenal adipose tissue (PRAT), a component of visceral adipose tissue, has been recently recognized as an important factor that contributes to the maintenance of the cardiovascular system and kidney homeostasis. PRAT is a complex microenvironment consisting of a mixture of white adipocytes and dormant and active brown adipocytes, associated with predipocytes, sympathetic nerve endings, vascular structures, and different types of inflammatory cells. In this review, we summarize the current knowledge about PRAT and discuss its role as a major contributing factor in the pathogenesis of hypertension, obesity, chronic renal diseases, and involvement in tumor progression. The new perspectives of PRAT as an endocrine organ and recent knowledge regarding the possible activation of dormant brown adipocytes are nowadays considered as new areas of research in obesity, in close correlation with renal and cardiovascular pathology. Supplementary PRAT complex intervention in tumor progression may reveal new pathways involved in carcinogenesis and, implicitly, may identify additional targets for tailored cancer therapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Cao, Gui, Ting Gong, Yue Du, Yicun Wang, Tongtong Ge, and Jingyu Liu. "Mechanism of metformin regulation in central nervous system: Progression and future perspectives." Biomedicine & Pharmacotherapy 156 (December 2022): 113686. http://dx.doi.org/10.1016/j.biopha.2022.113686.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Abdi, Esmat, Saeid Latifi‐Navid, and Hamid Latifi‐Navid. "Long noncoding RNA polymorphisms and colorectal cancer risk: Progression and future perspectives." Environmental and Molecular Mutagenesis 63, no. 2 (February 2022): 98–112. http://dx.doi.org/10.1002/em.22477.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Whitfield-Gabrieli, Susan. "13.3 INTRINSIC FUNCTIONAL ARCHITECTURE PREDICTS PROGRESSION OF FUTURE MOOD PROBLEMS IN CHILDREN." Journal of the American Academy of Child & Adolescent Psychiatry 60, no. 10 (October 2021): S278. http://dx.doi.org/10.1016/j.jaac.2021.07.626.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Fujino, Yuri, Hiroshi Murata, Chihiro Mayama, and Ryo Asaoka. "Applying “Lasso” Regression to Predict Future Visual Field Progression in Glaucoma Patients." Investigative Opthalmology & Visual Science 56, no. 4 (April 10, 2015): 2334. http://dx.doi.org/10.1167/iovs.15-16445.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Grant, EN, W. Tao, M. Craig, D. McIntire, and K. Leveno. "Neuraxial analgesia effects on labour progression: facts, fallacies, uncertainties and the future." BJOG: An International Journal of Obstetrics & Gynaecology 122, no. 3 (August 4, 2014): 288–93. http://dx.doi.org/10.1111/1471-0528.12966.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Shorey, Shefaly, Mien Li Goh, Shin Yuh Ang, Lina Ang, M. Kamala Devi, and Emily Ang. "The Progression and Future of Nursing in Singapore: A Descriptive Qualitative Study." Journal of Transcultural Nursing 30, no. 5 (January 28, 2019): 512–20. http://dx.doi.org/10.1177/1043659618823909.

Повний текст джерела

Анотація:

Introduction: Nursing professionalism and nursing identity are important for retention of nurses. Despite of much attention on nurses in Singapore, there is still a shortage of nurses. This study aims to understand the perceptions of the progression and future of the nursing profession in Singapore. Methodology: A descriptive qualitative study design was used. The participants were 20 nurse educators, clinical nurses, and student nurses. Data were collected through focus group and online interviews and analyzed thematically. Results: Nurses felt a need to bridge the theory–practice gap and various factors to the underlying cause of the shortage of nurses were highlighted. Nurses shared their desires to see greater autonomy among nurses and a greater focus on community nursing in the future. Discussion: Collaboration between nurse academics and clinical nurses may bridge the theory–practice gap. To reduce the issue of the shortage of nurses, efforts to promote nursing professionalism are required.

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Kantarci, K., R. C. Petersen, B. F. Boeve, D. S. Knopman, S. D. Weigand, P. C. O’Brien, M. M. Shiung, et al. "DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment." Neurology 64, no. 5 (March 7, 2005): 902–4. http://dx.doi.org/10.1212/01.wnl.0000153076.46126.e9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Razali, S. Z., R. Yunus, Suraya Abdul Rashid, H. N. Lim, and B. Mohamed Jan. "Review of biodegradable synthetic-based drilling fluid: Progression, performance and future prospect." Renewable and Sustainable Energy Reviews 90 (July 2018): 171–86. http://dx.doi.org/10.1016/j.rser.2018.03.014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Lipton, Richard B., and Marcelo E. Bigal. "Looking to the Future: Research Designs for Study of Headache Disease Progression." Headache: The Journal of Head and Face Pain 48, no. 1 (December 20, 2007): 58–66. http://dx.doi.org/10.1111/j.1526-4610.2007.00976.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Rafalska, Agnieszka, Jolanta Franczuk, Paweł Franczuk, Hanna Augustyniak‑Bartosik, and Magdalena Krajewska. "Stratifying risk for progression in IgA nephropathy: how to predict the future?" Polish Archives of Internal Medicine 124, no. 7-8 (May 14, 2014): 365–72. http://dx.doi.org/10.20452/pamw.2341.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Sharif, Amer A., Iain Blair, Nabila F. Taha, and Tom Loney. "Health systems in the United Arab Emirates: progression, challenges and future directions." International Journal of Behavioural and Healthcare Research 4, no. 3/4 (2013): 270. http://dx.doi.org/10.1504/ijbhr.2013.058859.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Del Negro, Ilaria, Sara Pez, Gian Luigi Gigli, and Mariarosaria Valente. "Disease Activity and Progression in Multiple Sclerosis: New Evidences and Future Perspectives." Journal of Clinical Medicine 11, no. 22 (November 9, 2022): 6643. http://dx.doi.org/10.3390/jcm11226643.

Повний текст джерела

Анотація:

Multiple sclerosis (MS) is a chronic, debilitating, autoimmune-mediated, inflammatory disease of the central nervous system (CNS), in which a combination of inflammation, demyelination and axonal degeneration takes place with extreme highly interpersonal variability [...]

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Beretta, Giovanni Luca. "Nanostrategies: The Future Medicine for Fighting Cancer Progression and Drug Resistance 2.0." International Journal of Molecular Sciences 23, no. 22 (November 21, 2022): 14486. http://dx.doi.org/10.3390/ijms232214486.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Luttringer, Olivier, Todd Fox, Luminita Pricop, Corine Gaillez, Helene Karcher, Witold Wiecek, Zuzanna Angehrn, and Billy Amzal. "Secukinumab's effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5." Clinical and Experimental Rheumatology 39, no. 5 (August 31, 2021): 931–37. http://dx.doi.org/10.55563/clinexprheumatol/ic89a8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Taylor, Jeremy M. G., Menggang Yu, and Howard M. Sandler. "Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer." Journal of Clinical Oncology 23, no. 4 (February 1, 2005): 816–25. http://dx.doi.org/10.1200/jco.2005.12.156.

Повний текст джерела

Анотація:

Purpose Following treatment for localized prostate cancer, men are monitored with serial prostate-specific antigen (PSA) measurements. Refining the predictive value of post-treatment PSA determinations may add to clinical management, and we have developed a model that predicts future PSA values and the time to future clinical recurrence for individual patients. Patients and Methods Data from 934 patients treated between 1987 and 2000 were used to develop a comprehensive statistical model to fit the clinical recurrence events and patterns of PSA data. A logistic model was used for the probability of cure, mixed models were used for serial PSA measurements, and a proportional hazards model was used for recurrences. Data available through February 2001 were fit to the model, and data collected between February 2001 and September 2003 were used for validation. Results T-stage, baseline PSA, and radiotherapy dosage are all associated with probability of cure. The risk of clinical recurrence in those not cured is strongly affected by the slope of PSA values. We show how the model can be used for individual monitoring of disease progression. For each patient the model predicts, based on baseline characteristics and all post-treatment PSA values, the probability of future clinical recurrences and future PSA values. The model accurately predicts risk of recurrence and future PSA values in the validation data set. Conclusion This predictive information on future PSA values and the risk of clinical relapse for each individual patient, which can be updated with each additional PSA value, may prove useful to patients and physicians in determining post-treatment salvage strategies.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Rus, Daniela. "The Machines from Our Future." Daedalus 151, no. 2 (2022): 100–113. http://dx.doi.org/10.1162/daed_a_01903.

Повний текст джерела

Анотація:

Abstract While the last sixty years have defined the field of industrial robots and empowered hard-bodied robots to execute complex assembly tasks in constrained industrial settings, the next sixty years will usher in our time with pervasive robots that come in a diversity of forms and materials and help people with physical tasks. The past sixty years have mostly been inspired by the human form, but the form diversity of the animal kingdom has broader potential. With the development of soft materials, machines and materials are coming closer together: machines are becoming compliant and fluid-like materials, and materials are becoming more intelligent. This progression raises the question: what will be the machines from our future?

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Rus, Daniela. "The Machines from Our Future." Daedalus 151, no. 2 (2022): 100–113. http://dx.doi.org/10.1162/daed_a_01903.

Повний текст джерела

Анотація:

Abstract While the last sixty years have defined the field of industrial robots and empowered hard-bodied robots to execute complex assembly tasks in constrained industrial settings, the next sixty years will usher in our time with pervasive robots that come in a diversity of forms and materials and help people with physical tasks. The past sixty years have mostly been inspired by the human form, but the form diversity of the animal kingdom has broader potential. With the development of soft materials, machines and materials are coming closer together: machines are becoming compliant and fluid-like materials, and materials are becoming more intelligent. This progression raises the question: what will be the machines from our future?

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!